OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd. filed this Form 6-K on December 21, 2023, reporting entry into an at-the-market equity offering arrangement dated December 20, 2023. The filing does not provide operating results for a specific quarter or year-to-date period.
Offering and Key Financial Terms
- The company may offer and sell ordinary shares with aggregate gross proceeds of up to $4.0 million through B. Riley Securities, Inc., acting as sales agent or principal.
- Shares may be sold from time to time at prevailing market prices through Nasdaq Capital Market or another existing U.S. trading market, subject to the company’s instructions regarding timing, volume and minimum price.
- OKYO is not obligated to sell any shares, and either party may suspend the offering with proper notice.
- B. Riley may receive a cash commission of up to 3.0% of gross sales proceeds.
- The company will reimburse eligible legal expenses of up to $75,000, plus up to $5,000 per calendar quarter for continuing diligence.
- Because there is no minimum offering amount, actual proceeds, commissions and expenses cannot be determined from the filing.
- The filing provides no revenue, profit, cash flow, margin, debt or liquidity figures.
Material Changes Versus the Prior Comparable Period
No comparable-period financial information or operating performance is disclosed. The material development is the establishment of a potential equity financing facility for up to $4.0 million.
Outlook, Risks and Unusual Items
- Any financing proceeds are uncertain because sales are discretionary and depend on market conditions and the company’s instructions.
- Issuance of ordinary shares may dilute existing shareholders; the filing does not state the number of shares that could be issued.
- Sales will be made at market prices and therefore may be affected by share-price volatility, trading liquidity and demand.
- The offering is supported by the company’s effective Form F-3 shelf registration statement filed June 8, 2023 and declared effective June 14, 2023.
- The agreement contains customary representations, warranties and covenants, as well as indemnification and contribution obligations in favor of B. Riley for specified liabilities, including Securities Act liabilities.
- Carey Olsen (Guernsey) LLP provided a legal opinion regarding the legality of issuing and selling the shares.
Important Facts for Investors to Verify
- Whether any shares have actually been sold and the resulting gross and net proceeds.
- The number of shares issued, the average sale price and the resulting dilution to existing shareholders.
- Use of proceeds and the company’s cash runway following any sales.
- Applicable commissions, legal reimbursements and other offering expenses.
- Current trading price, market liquidity and any subsequent amendments, suspensions or termination of the offering.